Heterogeneity in reagents from laboratory to laboratory is a major impediment to comparing and replicating results. This has proven to be particularly true of synthetic Abeta, primary cultures and mouse colonies. The goal of Specific Aim 1 is to provide radioactive and non-radioactive synthetic Abeta peptides of standard quality and purity to all Projects. Synthetic Abeta produced at the W. M. Keck Facility at Yale University will be purified using high-performance liquid chromatography (HPLC) and the final products characterized by analytical reverse phase HPLC, amino acid analysis, laser desorption mass spectrometry and circular dichroism spectrometry. Peptide will be labeled by iodination and [125]l-tyramine-cellobiose.
Specific Aim 2 is to maintain a mouse colony that can provide genetically modified mice (young, aged, and/or pregnant) and/or tissues to the three projects located in the United States. Breeding, genotyping and aging will thereby be centralized. Mouse lines maintained by the core will include: APOE knockout, hAPOEepsilon3 and epsilon4+/+ on APOE knockout background, floxed LRP, and the neuronal- and glial- Cre-recombinase mice with which they will be crossed. Finally, core staff will teach members of all projects in standardized methods of tissue culture. The goal of the Core B is to provide standardized materials to the four projects that comprise the scientific portion of the program project. These include synthetic Abeta compound in the form(s) thought to be toxic to neurons, and genetically engineered mice that will be used to test pathways regulating production of Abeta.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010491-14
Application #
7916716
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
14
Fiscal Year
2009
Total Cost
$279,282
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-121
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-129
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Ghani, Mahdi; Reitz, Christiane; Cheng, Rong et al. (2015) Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurol 72:1313-23

Showing the most recent 10 out of 198 publications